PurePEG LLC

PurePEG LLC is a leading supplier of high-quality, monodispersed polyethylene glycol (PEG) products with various repeating units (spacer length), end functional groups (X and Y), and various molecular architecture (linear, branched, and multi-armed). Founded in 2012, PurePEG has pioneered the development of pure, monodispersed PEGs with precise molecular weights through innovative PurePEG Technology. The company has made significant contributions to the biomedical field, particularly in the treatment of breast cancer, by developing the first acid functionalized PEG used in conjugating antibody and toxin for ADC drug therapy. With 12 pegylated drugs approved by the FDA to treat chronic diseases, PEG's role in biological therapies has seen significant growth. PurePEG remains unrivaled in the market due to its superior quality and capability to manufacture long-chain PEGs. The company operates at the forefront of PEG manufacturing, continually achieving breakthroughs in research and development. PurePEG's expertise spans across the Biotechnology, Manufacturing, and Supply Chain industries, positioning it as a global leader in the production of PEGs for biomedical applications. As a potential investment opportunity, PurePEG presents a strong foothold in a rapidly growing market with a proven track record of innovation and quality production.